Floatz logo

Solriamfetol

Sleep Disorder

Duke UniversitySmall moleculePhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

13 Active assets in the Sleep Disorder cohort.

Asset / SponsorPhaseRating
Trazodone
Johns Hopkins University
Phase 4BB
Armodafinil
Cephalon
Phase 4BB
Rasagiline
Technische Universität Dresden
Phase 4BB
Olanzapine
Central Institute of Psychiatry, Ranchi, India
Phase 4BB
Melatonin
Duke University
Phase 3BB

View all 34 →

Same molecule, other indications

Solriamfetol is also rated in:

hypersomniaActive
BB
Indicative · Phase 2
67 / 100
View asset →
long COVID-19Active
B
Indicative · Phase 2
62 / 100
View asset →
major depressive disorderActive
CCC
Indicative · Phase 3
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →